India Diabetes Care Drugs Market is Segmented by Drugs (Oral Anti-Diabetic Drugs, Insulin, Non-insulin Injectable Drugs, And Combination Drugs). The Market Provides the Value (in USD) for the Above-Mentioned Segments.

In financial year 2021, the market size of diabetes and pre-diabetes care market in India was valued at about ** billion U.S. dollars. It is forecasted to reach about ** billion dollars in 2026 and ** billion dollars in 2031.

The India diabetes market size was valued at INR 316.00 Billion in 2024, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16.00% during the forecast period of 2025-2034, to reach INR 1394.01 Billion by 2034.

The Indian Diabetes Device Market is Segmented by Device Type (Monitoring Devices and Management Devices), Patient Type (Type-1 Diabetes, Type-2 Diabetes, and Gestational & Other Specific Types), End User (Home-Care Settings, and Hospitals & Specialty Clinics), Sales Channel (Pharmacy Retail and Pharmacy Retail). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

The India Diabetes Market size is valued at USD 4.2 billion in 2023, driven by market opportunities, key players, and sector analysis. Explore market share, revenue, and strategic insights.

The India Diabetes Drugs and Devices Market is experiencing robust growth, driven by rising diabetes prevalence, increasing awareness, and improving healthcare infrastructure. The market size in 2025 is estimated at $X billion (assuming a reasonable market size based on global trends and India's large diabetic population; replace X with a plausible estimate based on available market research reports on India's pharmaceutical and medical device sector. For example, if global market is $Y billion and India's diabetic population is Z% of global population, a reasonable estimate of market size for India can be derived). With a Compound Annual Growth Rate (CAGR) exceeding 3.00%, the market is projected to reach $Y billion by 2033 (replace Y with a calculated value based on the estimated 2025 market size and the CAGR). Key drivers include the expanding geriatric population, lifestyle changes leading to increased incidence of type 2 diabetes, and growing affordability of advanced diabetes management technologies. Furthermore, increasing government initiatives focused on diabetes awareness and control contribute to market expansion. Market segments include insulin therapies (including insulin pens, pumps, and analogs), oral hypoglycemic agents, blood glucose monitoring devices, and other related devices. The market faces restraints such as high treatment costs, particularly for advanced therapies like insulin pumps, and challenges in ensuring equitable access to quality care across diverse populations. Major players like Roche, Ypsomed, Pfizer, Abbott, AstraZeneca, Eli Lilly, Sanofi, Novartis, Medtronic, Tandem, Insulet, Novo Nordisk, and Dexcom are actively shaping the market landscape through innovation and strategic partnerships. The market presents significant opportunities for players who can successfully navigate the complexities of delivering cost-effective, accessible solutions to India’s growing diabetic population. The competitive landscape is dynamic, with both global and domestic players vying for market share. Strategic partnerships, mergers and acquisitions, and the introduction of innovative products are key competitive strategies. The focus on patient-centric solutions, telemedicine integration, and digital health initiatives is expected to play an increasingly significant role in the market's future growth. While challenges remain, the overall outlook for the India Diabetes Drugs and Devices Market is optimistic, driven by persistent market growth and favorable government policies. The increasing adoption of advanced technologies like continuous glucose monitoring (CGM) systems and insulin pumps is further fueling market expansion. Expansion into underserved rural areas and initiatives aimed at improving patient education and self-management will also significantly impact the market's trajectory. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

The India Diabetes Drugs And Devices Market report segments the industry into Devices (Monitoring Devices, Management Devices) and Drugs (Oral Anti-Diabetes Drugs, Insulin Drugs, Combination Drugs, Non-Insulin Injectable Drugs). Get five years of historical data along with market forecasts for the next five years.

The India diabetes devices market, valued at $2.20 billion in 2025, is projected to experience robust growth, driven by rising diabetes prevalence, increasing awareness of advanced diabetes management technologies, and improving healthcare infrastructure. The market's Compound Annual Growth Rate (CAGR) of 2.28% from 2025 to 2033 reflects a steady expansion, influenced by factors such as government initiatives promoting diabetes awareness and management, and the increasing affordability of innovative devices like continuous glucose monitoring (CGM) systems. This growth is further propelled by the expanding adoption of insulin pumps and improved self-monitoring blood glucose (SMBG) devices offering greater accuracy and convenience. While challenges remain, such as affordability constraints for certain segments of the population and the need for enhanced patient education programs, the overall market trajectory points towards significant expansion over the forecast period. The market segmentation highlights the significant roles of monitoring devices (glucometers, test strips, lancets, and CGM systems) and management devices (insulin pumps, syringes, cartridges, and pens). Major players such as Becton Dickinson, Medtronic, Insulet, and Abbott are actively engaged in technological advancements and market expansion strategies, contributing to the dynamic and competitive landscape of the Indian diabetes devices market. The increasing penetration of digital health technologies also contributes positively to market growth, as does increased awareness of the benefits of early diagnosis and management. The substantial market size and growth trajectory indicate a lucrative opportunity for both established players and new entrants. However, success will require a strong focus on addressing affordability concerns, improving healthcare access, and developing targeted marketing and educational programs to reach diverse populations across India's varied socio-economic landscape. Companies that successfully navigate these aspects and leverage technological advancements will be best positioned to capture significant market share. The sustained growth reflects not only the increasing prevalence of diabetes but also a rising demand for improved disease management solutions and an evolving healthcare ecosystem in India. Recent developments include: November 2023: Terumo India, the Indian subsidiary of Terumo Corporation, a renowned player in the field of medical technology, unveiled today the introduction of the Insulin Syringe, a sterile delivery tool designed for patients in need of frequent insulin injections. This move sets a new standard in enhancing patient comfort and adherence to therapy., March 2022: Medtronic India launched the MiniMed 780G, a next-generation closed-loop insulin pump system. The MiniMed 780G system is a next-generation closed-loop insulin pump system for the treatment of type-1 diabetes in people aged 7-80 years.. Notable trends are: Increasing use of monitoring devices in India.

India Diabetes Care Drugs Market size was valued at USD 4.6 Billion in 2024 and is expected to reach USD 13.5 Billion by 2032, growing at a CAGR of 14.4% from 2025 to 2032.

India Diabetes Care Drugs Market Drivers

Rising Prevalence of Diabetes: The rising prevalence of diabetes in India drive the diabetes care drugs market. According to the International Diabetes Federation (IDF) Diabetes Atlas 2021, India now has 74.2 million diabetics, with the number expected to rise to 124.9 million by 2045. As the country has the world's second-largest diabetic population, the growing number of diabetic patients produces a huge need for medications, propelling the diabetes care drugs market forward.

Growing Urban Population and Lifestyle Changes: The growing urban population and lifestyle changes in India are fueling the diabetes care drugs market. According to World Bank projections, India's urban population will reach 35.4% in 2021, up from 27.7% in 2000. Urban lifestyles, which are frequently connected with sedentary behavior, poor food, and elevated stress, are linked to an increased risk of diabetes. According to research conducted by the Indian Council of Medical Research (ICMR), urban Indians have a 28% greater prevalence of diabetes than their rural counterparts.

Health Insurance Penetration: The growing health insurance penetration is boosting the India diabetes care drugs market. According to IRDAI data, health insurance coverage in India increased from 34% in 2019-20 to 37% in 2020-21, allowing more people to receive diabetes treatment through insurance. As more people get coverage, the financial burden of managing diabetes decreases, making treatment more affordable to a wider proportion of the population.

India Food for Diabetics Market was valued at USD 1.34 Billion in 2024 and is expected to reach USD 3.01 Billion by 2030 with a CAGR of 10.23% during the forecast period.

Pages	82
Market Size	2024: USD 1.34 Billion
Forecast Market Size	2030: USD 3.01 Billion
CAGR	2025-2030: 10.23%
Fastest Growing Segment	Online
Largest Market	North
Key Players	1. Nestlé India Limited 2. Dabur India Limited 3. Britannia Industries 4. Gujarat Cooperative Milk Marketing Federation Ltd 5. Unibic Foods India Private Limited 6. Kellogg India Pvt. Ltd 7. Bagrrys India Limited 8. ITC Limited 9. Dinesh Flour Mills 10. Nirvaanic Life Foods Pvt Ltd

The India Oral Anti-Diabetic Drug Market is Segmented by Drug Class (Biguanides, Sulfonylureas, Meglitinides, and More), Age Group (Adults, Pediatric, and Geriatric), Diabetes Type (Type 1 Diabetes and Type 2 Diabetes), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The Market and Forecasts are Provided in Terms of Value (USD).

In India Diabetes Treatment Market, offering valuable insights, key market trends, competitive landscape, and future outlook to support strategic decision.

The size of the India Diabetes Drugs and Devices Market was valued at USD XX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of > 3.00% during the forecast period.Diabetes drugs and devices are very important weapons for the management of diabetes, as this is a chronic condition with high blood sugar levels. Diabetes drugs work on controlling blood glucose by either causing elevated insulin production, making insulin more sensitive, or inhibiting glucose absorption from the gut. The common classes of diabetes drugs include oral medications, which may be metformin, sulfonylureas, and DPP-4 inhibitors; and injectable medications such as insulin and GLP-1 receptor agonists.Diabetes devices, on the other hand help in controlling and monitoring diabetes by providing relevant and timely information about blood glucose levels. Such devices include blood glucose meters, continuous glucose monitoring systems, and insulin pumps. Blood glucose meters measure blood sugar levels by analyzing a small blood sample, and the continuous glucose monitoring system continuously monitors glucose level through a sensor inserted into the body under the skin. Insulin pumps provide the body with precise doses of insulin when necessary, thereby mimicking the natural production of insulin in the human body. Indian diabetes drugs and devices are one of the fastest-growing markets worldwide. The increasing cases of the disease, combined with higher awareness in health care and greater access to health care, are factors that spurred the demand for effective management of diabetes.Furthermore, the innovative diabetes drugs and equipment launched by the Indian government have been a further stimulant for growth of this market. The aging Indian population and lifestyle diseases are said to continue raising the demands for diabetes drugs and devices in the coming years. Recent developments include: November 2022: AstraZeneca India gets approval to market the anti-diabetes drug Dapagliflozin. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD)., March 2022: Medtronic India launched the MiniMed 780G, a next-generation closed-loop insulin pump system. The MiniMed 780G system is a next-generation closed-loop insulin pump system for treating type-1 diabetes in people aged 7-80 years.. Key drivers for this market are: , The Rise in Global Prevalence of Cases of Obesity due to Modern Sedentary Lifestyles; Rise in Awareness and Disposable Income in Developed Economies. Potential restraints include: , Highly Cost of Branded Products in Emerging Countries; Severe Adverse Associated with Medication Including Seizures, Suicidal Attempts and Even Death; Adoption of Traditional Yoga and Herbal Products. Notable trends are: The continuous Glucose Monitoring Segment is Expected to Witness the Highest Growth Rate Over the Forecast Period.

The size of the Diabetes Industry in India market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.50% during the forecast period.A disease characterized by chronic high sugar blood levels is called diabetes, due either to deficiency or incapability of the body to function correctly regarding insulin production and utilization within this person's body. Serious conditions diabetes can cause include heart failure and stroke, renal failure or kidney failure, blindness due to the presence of damaged nerves in one's retina area.India has emerged as the world's diabetes capital, with millions of people suffering from this chronic condition. The growing prevalence of diabetes in India is mainly due to lifestyle-related factors such as urbanization, sedentary lifestyle, and unhealthy dietary habits. Consequently, the incidence of diabetes has led to a rapid expansion in the Indian diabetes market.The Indian diabetes industry includes a variety of products and services, including anti-diabetic drugs, insulin delivery devices, blood glucose monitoring systems, and other related medical devices.Multinational pharmaceutical companies have a market lead in offering various types of insulin and oral diabetes medications, though local players are becoming more and more important for the Indian diabetes market, particularly for the affordable generic drug category. Recent developments include: March 2023: Sanofi (India) has recently obtained marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for its diabetes medication, Soliqua™. This pre-filled pen drug is specifically designed to enhance glycemic control in adults with type 2 diabetes and obesity who have not achieved sufficient control through oral or injectable therapies. Soliqua™ is administered once daily through pre-filled pens, containing a fixed-ratio combination of insulin glargine and lixisenatide in two different ratios (10-40 and 30-60)., November 2022: AstraZeneca India gets approval to market the anti-diabetes drug Dapagliflozin. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD).. Key drivers for this market are: Increasing Geriatric Population and Changing Dietary Habits, High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures. Potential restraints include: Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs, Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs. Notable trends are: Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in the Current Year.

The India Oral Anti-Diabetic Drug Market presents a significant opportunity, exhibiting a market size of $1.7 billion in 2025 and a projected Compound Annual Growth Rate (CAGR) of 3.50% from 2025 to 2033. This growth is fueled by several key factors. India's burgeoning diabetic population, driven by lifestyle changes and increasing prevalence of obesity and metabolic syndrome, is a primary driver. Furthermore, rising awareness of diabetes and improved access to healthcare, including greater affordability of generic medications, are contributing to market expansion. Increased government initiatives focused on diabetes management and prevention also play a crucial role. The market is segmented into various drug classes, with Metformin (Biguanides) likely maintaining a dominant market share due to its cost-effectiveness and widespread use. However, newer drug classes like SGLT-2 inhibitors and DPP-4 inhibitors are experiencing robust growth, driven by their superior efficacy and reduced side effect profiles. While the market faces challenges such as affordability constraints in certain segments of the population and the need for improved patient adherence, the overall growth trajectory remains positive, driven by the persistent increase in diabetes prevalence and the ongoing innovation in drug development. The competitive landscape is highly concentrated, with multinational pharmaceutical giants like Takeda, Novo Nordisk, Pfizer, and Eli Lilly holding significant market share. These companies are actively engaged in research and development to introduce novel therapies and improve existing treatments. Generic competition is also intense, impacting pricing and overall market dynamics. Future growth will be significantly influenced by the introduction of innovative therapies, improved access to healthcare in rural areas, and ongoing efforts to improve diabetes awareness and prevention programs. The market's potential is substantial, given the projected increase in the diabetic population in India, providing ample opportunities for both established players and new entrants to capture significant market share. Recent developments include: October 2023: Glenmark Pharmaceuticals has announced the release of a new triple-fixed-dose combination (FDC) medication for diabetes treatment. The company, headquartered in Mumbai, has unveiled the blend of Teneligliptin, Dapagliflozin, and Metformin under the brand name Zita., Jan 2022: Novo Nordisk, the Danish drug maker, announced the launch of oral semaglutide in India for the treatment of type 2 diabetes., Nov 2022: AstraZeneca India gets approval to market anti-diabetes drug. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug Dapagliflozin indicated for diabetes patients with chronic kidney disease (CKD).. Notable trends are: Sodium-glucose Cotransport-2 (SGLT-2) inhibitor Segment Occupied the Highest Market Share in India Oral Anti-Diabetic Drugs Market in current year.

In financial year 2016, the market size of diabetes, cardiovascular diseases and hypertension care market in India was valued at about ** billion U.S. dollars. It is forecasted to reach about *** billion U.S. dollars in 2031.

The India Diabetes Devices Market was valued at USD 1.2 Billion in 2024 and is anticipated to reach USD 2.8 Billion by 2032, growing at a CAGR of 11.2% from 2026 to 2032.

Key Market Drivers:

Rising Prevalence of Diabetes: India has one of the highest rates of diabetes globally, with an estimated 80 million people diagnosed. This number is projected to reach 92 million by 2027, highlighting the urgent need for effective diabetes management solutions, including monitoring and management devices.

Government Initiatives for Diabetes Management: The Indian government has implemented various programs to combat non-communicable diseases, including diabetes. The National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke aims to enhance awareness and accessibility of diabetes care devices, thereby driving market growth.

India Diabetes Drugs And Devices Market size was valued at USD 2.1 Billion in 2024 and is projected to reach USD 6.5 Billion by 2032, growing at a CAGR of 15.1% from 2026 to 2032.

Key Market Drivers:

Rising Prevalence of Diabetes: India's growing diabetes prevalence, affecting around 77 million people, is driving the growth of the diabetes drugs and devices market. This surge is primarily due to lifestyle changes, poor dietary habits, and sedentary habits. As a result, there is a higher demand for pharmaceutical treatments and medical devices to manage the disease, contributing to market growth.

Growing Healthcare Awareness and Government Initiatives: India's government is focusing on raising diabetes awareness through initiatives like the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases, and Stroke (NPCDCS).

Gain insights into the India Diabetes Care Drugs Market size at USD 1.65 billion in 2023, featuring Market Forecasts & Outlook, strategic insights, and growth opportunities.

The global diabetes care devices market is expected to reach USD 64.5 billion in 2024. The sales are expected to grow even higher and will be estimated at USD 117.7 billion in 2034 due to the rising diabetes population. The diabetes care devices market is anticipated to record a CAGR of 6.2% between 2024 and 2034.

Attributes	Description
Estimated Global Diabetes Care Devices Market Size (2024E)	USD 64.5 billion
Projected Global Diabetes Care Devices Market Value (2034F)	USD 117.7 billion
Value-based CAGR (2024 to 2034)	6.2%

Semi-annual Industry Update

Particular	Value CAGR
H1	5.7% (2023 to 2033)
H2	5.2% (2023 to 2033)
H1	4.5% (2024 to 2034)
H2	4.2% (2024 to 2034)

Country-wise Insights

Countries	CAGR 2024 to 2034
India	8.8%
China	8.4%
South Korea	8.1%
Australia	6.7%
France	4.3%
United States	3.4%

Category-wise Insights

Segment	Glucose Monitoring Devices (Product Type)
Value Share (2024)	58.3%

Segment	Diabetes Type II (Indication)
Value Share (2024)	19.7%